Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cabaletta Bio Inc (NQ: CABA )

11.18 +1.09 (+10.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cabaletta Bio Inc

< Previous 1 2 3 4 5 Next >
CABA Stock Investigation: Robbins LLP Investigates Cabaletta Bio, Inc. (CABA) on Behalf of Shareholders
From Robbins LLP
Via Business Wire
Cabaletta Bio, Inc. (NASDAQ:CABA) Investor Notice: Lawsuit Alleges Securities Laws Violations
San Diego, CA -- (SBWIRE) -- 03/18/2022 -- An investor, who purchased shares of Cabaletta Bio, Inc. (NASDAQ:CABA), filed a lawsuit over alleged violations of Federal Securities Laws by Cabaletta Bio,... 
Via SBWire
10 Biggest Price Target Changes For Friday
Keybanc cut the price target on AMETEK, Inc. (NYSE: AME) from $160 to $155. AMETEK shares rose 1% to close at $132.75 on Thursday. 
Via Benzinga
Recap: Cabaletta Bio Q4 Earnings
Cabaletta Bio (NASDAQ:CABA) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
ROSEN, A TOP RANKED LAW FIRM, Encourages Cabaletta Bio, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - CABA
WHY: New York, NY - (NewMediaWire) - March 15, 2022 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cabaletta Bio, Inc. (NASDAQ: CABA): (i) pursuant and/or... 
Via NewMediaWire
Investor Action Reminder: The Schall Law Firm Encourages Investors In Cabaletta Bio, Inc. With Losses Of $100,000 To Contact The Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Shareholder Action Notice: The Schall Law Firm Encourages Investors In Cabaletta Bio, Inc. With Losses Of $100,000 To Contact The Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
CABA LOSS ALERT: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Cabaletta Bio, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action CABA
WHY: New York, NY - (NewMediaWire) - March 11, 2022 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cabaletta Bio, Inc. (NASDAQ: CABA): (i) pursuant and/or... 
Via NewMediaWire
Shareholder Action Alert: The Schall Law Firm Encourages Investors In Cabaletta Bio, Inc. With Losses Of $100,000 To Contact The Firm
Los Angeles - (NewMediaWire) - March 10, 2022 -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Cabaletta Bio, Inc.... 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Investor Action Reminder: The Schall Law Firm Encourages Investors In Cabaletta Bio, Inc. With Losses Of $100,000 To Contact The Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Shareholder Action Notice: The Schall Law Firm Encourages Investors In Cabaletta Bio, Inc. With Losses Of $100,000 To Contact The Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Shareholder Action Alert: The Schall Law Firm Encourages Investors in Cabaletta Bio, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Investor Action Reminder: The Schall Law Firm Encourages Investors in Cabaletta Bio, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Shareholder Action Notice: The Schall Law Firm Encourages Investors in Cabaletta Bio, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Calliditas Therapeutics (NASDAQ:CALT... 
Via Benzinga
46 Biggest Movers From Yesterday
Gainers Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday. CMC Materials, Inc. (NASDAQ: CCMP) climbed 33.9% to close at $195.50 on... 
Via Benzinga
58 Biggest Movers From Yesterday
Gainers Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price... 
Via Benzinga
Mid-Afternoon Market Update: Dow Falls 100 Points; Terminix Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 0.30% to 35,544.59 while the NASDAQ fell 1.53% to 15,176.99. The S&P also fell, dropping 0.93% to 4,625.65. The U.S. has... 
Via Benzinga
50 Biggest Movers From Yesterday
Gainers Sidus Space, Inc. (NASDAQ: SIDU) shares jumped 143.8% to settle at $12.19 on Tuesday after the company priced its IPO at $5 per share, MIND Technology, Inc. (NASDAQ: MIND... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Galera Therapeutics (NASDAQ:GRTX 
Via Benzinga
Cabaletta Bio's Cell Therapy Fails To Show Activity At Low Doses In Skin Blistering Disorder
Cabaletta Bio Inc's (NASDAQ: CABA) DSG3-CAART fails to show biologic activity to date in the two lowest cell dose cohorts of Phase 1 trial mucosal Pemphigus... 
Via Benzinga
Mid-Day Market Update: Nasdaq Tumbles 200 Points; MIND Technology Shares Jump
Midway through trading Tuesday, the Dow traded down 0.17% to 35,588.72 while the NASDAQ fell 1.3% to 15,213. The S&P also fell, dropping 0.80% to 4,631.69. The U.S. has the... 
Via Benzinga
34 Stocks Moving In Tuesday's Mid-Day Session
Gainers Exicure, Inc. (NASDAQ: XCUR) rose 41.8% to $0.3830. Exicure’s Audit Committee recently concluded that Grant Corbett misreported raw data from certain R&D... 
Via Benzinga
Mid-Morning Market Update: Markets Mostly Lower; Producer Prices Rise 0.8% In November
Following the market opening Tuesday, the Dow traded up 0.06% to 35,673.60 while the NASDAQ fell 1.08% to 15,247.22. The S&P also fell, dropping 0.57% to 4,642.29. The U.S.... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021
Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD... 
Via Benzinga
Cabaletta Posts Cell Therapy Data From Third Cohort Of Autoimmune Skin Disorder Trial
Cabaletta Bio Inc (NASDAQ: CABA) has announced 28-day clinical data from the third dose cohort (500 million DSG3-CAART cells) in the DesCAARTes Phase 1 trial for... 
Via Benzinga
30 Stocks Moving In Wednesday's Mid-Day Session
Gainers Kadmon Holdings, Inc. (NASDAQ: KDMN) shares jumped 72.6% to $9.15. Sanofi announced Wednesday it has agreed to acquire New York-based biopharma Kadmon in a $1.9 billion... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Cellectar Biosciences (NASDAQ:CLRB 
Via Benzinga
63 Biggest Movers From Yesterday
Gainers Support.com, Inc. (NASDAQ: SPRT) shares surged 41.1% to settle at $19.70 on Thursday on abnormally high volume. TSR, Inc. (NASDAQ: TSRI) shares rose 28.1% to close at $11... 
Via Benzinga
Cabaletta Bio's Cell Therapy Shows Encouraging Safety Profile In Autoimmune Skin Disorder
Cabaletta Bio Inc (NASDAQ: CABA) has announced 28-day data from the second dose cohort from the DesCAARTes Phase 1 trial of DSG3-CAART for mucosal-dominant... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.